Please assess the completion status of the following clinical trial:

Trial Title: A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CD20-positive B-CLL~* Rai Stage III/IV or Binet Stage C disease~* Rai Stage I/II or Binet Stage B disease that requires treatment~* Adequate baseline bone marrow function, unless there is clear evidence of extensive bone marrow involvement with tumor infiltration, myelodysplasia, or hypocellularity~* No previous treatment for CLL by chemotherapy, radiotherapy, or immunotherapy~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~* Life expectancy of greater than (\>) 6 months~Exclusion Criteria:~* Treatment with any other investigational agent or participation in another clinical trial within 28 days prior to the start of Cycle 1~* Transformation of CLL to aggressive B-cell malignancy~* Creatinine clearance less than equal to (\<=) 60 milliliters per minute (mL/min), calculated according to the formula of Cockcroft and Gault~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5 times the upper limit of normal (ULN)~* Total bilirubin greater than equal to (\>=) 3 x ULN~* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy~* History of sensitivity to mannitol (if bendamustine is to be administered)~* History of other malignancy that could affect compliance with the protocol or interpretation of results~* Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease or pulmonary disease~* Known active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks before the start of Cycle 1~* Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis~* Known infection with human immunodeficiency virus (HIV) seropositive status~* Presence of positive test results for hepatitis B (hepatitis B virus \[HBV\] surface antigen \[HBsAg\] and/or total hepatitis B core antibody \[anti-HBc\]) or hepatitis C (hepatitis C virus \[HCV\] antibody serology testing). Participants with chronic HBV infection, occult HBV infection, or past HBV infection will be excluded. Participants who have received IV immunoglobulin within 3 months of enrollment and who are anti-HBc positive but HBV deoxyribonucleic acid (DNA) negative will be considered for inclusion on the study by the Medical Monitor on a case-by-case basis. Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).~* Women who are pregnant or lactating~* Fertile men or women of childbearing potential unless 1) surgically sterile or 2) using an adequate measure of contraception such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly~* Concurrent (or within 7 days prior to the first dose of study treatment) systemic corticosteroid use except low-dose corticosteroid therapy used to treat an illness other than lymphoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Obinutuzumab + Fludarabine + Cyclophosphamide (Type: EXPERIMENTAL): Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6), fludarabine (25 mg/m\^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6), and cyclophosphamide (250 mg/m\^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6).
- Obinutuzumab + Bendamustine (Type: EXPERIMENTAL): Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6) and bendamustine (90 mg/m\^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6).

Based on this trial design, predict the completion outcome and termination type (if applicable).